Anti-Xa based dosing of enoxaparin in hematopoietic stem cell transplant and adoptive cell therapy patients: A single center experience

•Hematopoietic stem cell transplant and adoptive cellular therapies put patients at risk of clotting and bleeding.•In a retrospective cohort of patients receiving enoxaparin, anti-Xa based dosing resulted in decreased doses of enoxaparin.•Large randomized studies are needed to demonstrate the utilit...

Full description

Saved in:
Bibliographic Details
Published inThrombosis research Vol. 211; pp. 6 - 9
Main Authors Jizzini, Mazen, Akhtar, Othman Salim, Atwood, Kris, Ji, Wenyan, Pleskow, Jordan, Bat, Taha, Balderman, Sophia
Format Journal Article
LanguageEnglish
Published United States Elsevier Ltd 01.03.2022
Subjects
Anticoagulants - pharmacology
Anticoagulants - therapeutic use
Cell- and Tissue-Based Therapy
Enoxaparin - therapeutic use
Factor Xa Inhibitors
Hematopoietic Stem Cell Transplantation
Heparin, Low-Molecular-Weight
Humans
Venous Thromboembolism
Online AccessGet full text

Cover

More Information
Summary:•Hematopoietic stem cell transplant and adoptive cellular therapies put patients at risk of clotting and bleeding.•In a retrospective cohort of patients receiving enoxaparin, anti-Xa based dosing resulted in decreased doses of enoxaparin.•Large randomized studies are needed to demonstrate the utility of anti-Xa monitoring in this unique patient population.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0049-3848
1879-2472
DOI:10.1016/j.thromres.2022.01.012